Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
Multiple Sclerosis
Explore 182 assets in Multiple Sclerosis →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Beijing Boren Hospital
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07361094CT.gov Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy (this asset) | Beijing Boren Hospital | P1 | CC · 43 |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Fingolimod | Biogen | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Systemic Lupus Erythematosus | — | P1 | CC · 43 |
| Systemic Sclerosis | — | P1 | CC · 43 |
| Idiopathic Inflammatory Myopathy | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd19-bcma-dual-target-car-t-cell-therapy-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →